Trafalgar International (GCAN) Total Current Liabilities (2016 - 2026)
Trafalgar International (GCAN) posted Total Current Liabilities of $776464.0 for Q1 2026, up 4.58% on a QoQ basis from $742464.0 in Q4 2025, and down 23.05% year-over-year from $1.0 million in Q1 2025.
Analysis
Trafalgar International (GCAN) Total Current Liabilities (2016 - 2026) Analysis & Trends
Trafalgar International has reported Total Current Liabilities for 11 years, with the latest figure at $776464.0 in Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 23.05% year-over-year to $776464.0 in Q1 2026; TTM through Mar 2026 was $776464.0, a 23.05% decrease from a year earlier, with the FY2025 full-year figure at $742464.0, down 17.33% from the prior year.
- Total Current Liabilities was $776464.0 for Q1 2026 at Trafalgar International, up from $742464.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $1.1 million in Q3 2025, with the low at $742464.0 in Q4 2025.
- Average Total Current Liabilities over 5 years is $897704.7, with a median of $860874.0 recorded in 2024.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 44.13% in 2022, then slipped 23.05% in 2026.
- Over 5 years, Total Current Liabilities stood at $825277.0 in 2022, then climbed by 1.0% to $833508.0 in 2023, then climbed by 7.74% to $898058.0 in 2024, then declined by 17.33% to $742464.0 in 2025, then rose by 4.58% to $776464.0 in 2026.
- The last three Total Current Liabilities figures came in at $776464.0 (Q1 2026), $742464.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 37.11 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 354.06 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.31 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | 776,464.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 776,464.00 |
| Dec 31, 2025 | 742,464.00 |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 898,058.00 |
| Sep 30, 2024 | 860,874.00 |
| Jun 30, 2024 | 833,993.00 |
| Mar 31, 2024 | 839,333.00 |
| Dec 31, 2023 | 833,508.00 |
| Sep 30, 2023 | 856,570.00 |
| Jun 30, 2023 | 881,605.00 |
| Mar 31, 2023 | 848,618.00 |
| Dec 31, 2022 | 825,277.00 |
| Sep 30, 2022 | 862,190.00 |
| Jun 30, 2022 | 965,767.00 |
| Mar 31, 2022 | 998,504.00 |
| Dec 31, 2021 | 861,999.00 |
| Sep 30, 2021 | 782,506.00 |
| Jun 30, 2021 | 670,049.00 |